WO2007013041A3 - Monitoring of cardiac natriuretic peptides during diagnosis, managment, and treatment of cardiac diseases - Google Patents
Monitoring of cardiac natriuretic peptides during diagnosis, managment, and treatment of cardiac diseases Download PDFInfo
- Publication number
- WO2007013041A3 WO2007013041A3 PCT/IB2006/052578 IB2006052578W WO2007013041A3 WO 2007013041 A3 WO2007013041 A3 WO 2007013041A3 IB 2006052578 W IB2006052578 W IB 2006052578W WO 2007013041 A3 WO2007013041 A3 WO 2007013041A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cardiac
- natriuretic peptide
- inactive
- managment
- monitoring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008523521A JP5090348B2 (en) | 2005-07-29 | 2006-07-27 | Monitoring of cardiac natriuretic peptide during diagnosis, treatment and treatment of heart disease |
| US11/996,810 US20080221033A1 (en) | 2005-07-29 | 2006-07-27 | Monitoring of Cardiac Natriuretic Peptides During Diagnosis, Management, and Treatment of Cardiac Diseases |
| EP06780226.4A EP1913402B1 (en) | 2005-07-29 | 2006-07-27 | Monitoring of cardiac natriuretic peptides during diagnosis, managment, and treatment of cardiac diseases |
| ES06780226.4T ES2657087T3 (en) | 2005-07-29 | 2006-07-27 | Monitoring of cardiac natriuretic peptides during diagnosis, management and treatment of heart disease |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70392805P | 2005-07-29 | 2005-07-29 | |
| US60/703,928 | 2005-07-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007013041A2 WO2007013041A2 (en) | 2007-02-01 |
| WO2007013041A3 true WO2007013041A3 (en) | 2007-10-11 |
Family
ID=37683727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2006/052578 Ceased WO2007013041A2 (en) | 2005-07-29 | 2006-07-27 | Monitoring of cardiac natriuretic peptides during diagnosis, managment, and treatment of cardiac diseases |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080221033A1 (en) |
| EP (1) | EP1913402B1 (en) |
| JP (1) | JP5090348B2 (en) |
| CN (1) | CN101233411A (en) |
| ES (1) | ES2657087T3 (en) |
| WO (1) | WO2007013041A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7524635B2 (en) * | 2003-04-17 | 2009-04-28 | Biosite Incorporated | Methods and compositions for measuring natriuretic peptides and uses thereof |
| EP1731910A1 (en) * | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
| DE102007021443A1 (en) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnosis and risk stratification using NT-proET-1 |
| EP2467719A4 (en) * | 2009-08-19 | 2013-01-09 | Marker detection for characterizing the risk of cardiovascular disease or complications thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4415896A1 (en) * | 1994-05-05 | 1995-11-09 | Boehringer Mannheim Gmbh | Analysis system for monitoring the concentration of an analyte in the blood of a patient |
| US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| CN1185493C (en) * | 2001-11-16 | 2005-01-19 | 清华大学 | Intelligent microdestructive blood sugar tester measuring method and devcie |
| WO2003079979A2 (en) * | 2002-03-18 | 2003-10-02 | Scios Inc. | Method for treating congestive heart failure |
| WO2004046729A2 (en) * | 2002-11-21 | 2004-06-03 | The University Of Leicester | Bodily fluid markers of tissue hypoxia |
| CA2535971C (en) * | 2003-08-20 | 2018-04-10 | Biosite, Inc. | Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential |
| US7632234B2 (en) * | 2003-08-29 | 2009-12-15 | Medtronic, Inc. | Implantable biosensor devices for monitoring cardiac marker molecules |
| GB0329288D0 (en) * | 2003-12-18 | 2004-01-21 | Inverness Medical Switzerland | Monitoring method and apparatus |
| JP2007534363A (en) * | 2003-12-18 | 2007-11-29 | インバーネス メディカル スウィッツァーランド ゲーエムベーハー | Monitoring method and monitoring apparatus |
-
2006
- 2006-07-27 CN CNA2006800279193A patent/CN101233411A/en active Pending
- 2006-07-27 ES ES06780226.4T patent/ES2657087T3/en not_active Expired - Lifetime
- 2006-07-27 WO PCT/IB2006/052578 patent/WO2007013041A2/en not_active Ceased
- 2006-07-27 JP JP2008523521A patent/JP5090348B2/en not_active Expired - Fee Related
- 2006-07-27 EP EP06780226.4A patent/EP1913402B1/en not_active Expired - Lifetime
- 2006-07-27 US US11/996,810 patent/US20080221033A1/en not_active Abandoned
Non-Patent Citations (4)
| Title |
|---|
| BURGER ANDREW J ET AL: "Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study.", AMERICAN HEART JOURNAL, vol. 144, no. 6, December 2002 (2002-12-01), pages 1102 - 1108, XP002427034, ISSN: 0002-8703 * |
| GEGENHUBER ALFONS ET AL: "Time course of B-type natriuretic peptide (BNP) and N-terminal proBNP changes in patients with decompensated heart failure.", CLINICAL CHEMISTRY FEB 2004, vol. 50, no. 2, February 2004 (2004-02-01), pages 454 - 456, XP002427032, ISSN: 0009-9147 * |
| RADEMAKER M T ET AL: "CARDIAC NATRIURETIC PEPTIDES FOR CARDIAC HEALTH", CLINICAL SCIENCE, BIOCHEMICAL SOCIETY AND THE MEDICAL RESEARCH SOCIETY, LONDON,, GB, vol. 108, no. 1, January 2005 (2005-01-01), pages 23 - 36, XP009060567, ISSN: 0143-5221 * |
| RICHARDS MARK ET AL: "NT-proBNP in heart failure: therapy decisions and monitoring.", EUROPEAN JOURNAL OF HEART FAILURE : JOURNAL OF THE WORKING GROUP ON HEART FAILURE OF THE EUROPEAN SOCIETY OF CARDIOLOGY 15 MAR 2004, vol. 6, no. 3, 15 March 2004 (2004-03-15), pages 351 - 354, XP002427033, ISSN: 1388-9842 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009503490A (en) | 2009-01-29 |
| WO2007013041A2 (en) | 2007-02-01 |
| EP1913402A2 (en) | 2008-04-23 |
| ES2657087T3 (en) | 2018-03-01 |
| EP1913402B1 (en) | 2017-10-25 |
| JP5090348B2 (en) | 2012-12-05 |
| CN101233411A (en) | 2008-07-30 |
| US20080221033A1 (en) | 2008-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004103150A3 (en) | Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin | |
| WO2006009702A3 (en) | Liver disease-related methods and systems | |
| US20220241028A1 (en) | Prediction of blood perfusion difficulties based on biomarker monitoring | |
| WO2008055491A3 (en) | Diagnosis and risk assessment of pancreatic diabetes using mr-proadm | |
| WO2007001342A3 (en) | Exhaled breath condensate collection and assay system and method | |
| WO2005121788A3 (en) | Method for the early detection of renal disease and injury | |
| WO2007006858A3 (en) | Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same | |
| WO2003009806A3 (en) | Methods for evaluating pathologic conditions using extracellular rna | |
| WO2003096164A3 (en) | Medical information system | |
| WO2002014537A3 (en) | Methods for diagnosing and treating dysautonomia and other dysautonomic conditions | |
| EP2008581A3 (en) | Patient monitoring, diagnosis, and/or therapy systems and methods | |
| DE602007000529D1 (en) | Active medical implant, in particular device for stimulation, resynchronization, defibrillation and / or cardioversion, comprising means for predictive warning of an exacerbation of the disease state of the patient | |
| BR0111473A (en) | Methods for screening an individual for glycogen storage disease, for screening an individual for pomp disease, for monitoring the clinical condition of an individual with pomp disease, to estimate the efficacy of a therapeutic regimen for an individual with disease pompe and to determine the concentration of an oligosaccharide in a biological sample | |
| ATE435657T1 (en) | THERAPEUTIC PREPARATION OF HIGHLY PURE FVIIA AND METHOD FOR OBTAINING IT | |
| WO2003048775A3 (en) | Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases | |
| WO2005026687A3 (en) | Diagnosis and monitoring of hepatocellular carcinoma | |
| WO2006025028A3 (en) | Novel classification method of blood cells and tailor-made therapy and prevention based thereupon | |
| WO2005098429A3 (en) | System and method for real-time diagnosis, treatment, and therapeutic drug monitoring | |
| TW200622245A (en) | Abnormalities of phosphatase 2A (PP2A) for diagnosis and treatment of alzheimer's disease | |
| WO2000066782A3 (en) | Diagnostic assay for diabetes mellitus based on mutational burden | |
| WO2003024324A3 (en) | METHODS FOR IN VIVO EVALUATION OF A PHYSIOLOGICAL STRUCTURE OR FUNCTION USING POLARIZED129Xe | |
| WO2003034072A3 (en) | Diagnosis and therapy of conditions involving alms1 | |
| BR0318166A (en) | use of a sgk1 detection substance, detection kit, as well as a pharmaceutical composition that inhibits or activates its expression and / or function | |
| WO2007103303A3 (en) | Systems and methods using a dynamic expert system to provide patients with aesthetic improvement procedures | |
| Beniwal et al. | SpO2/FiO2 and PaO2/FiO2 for Predicting Intensive Care Admission in Wheezy Children: An Observational Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REEP | Request for entry into the european phase |
Ref document number: 2006780226 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006780226 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008523521 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11996810 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200680027919.3 Country of ref document: CN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 936/CHENP/2008 Country of ref document: IN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2006780226 Country of ref document: EP |